CSLLY - CSL Limited: Near-Term Outlook Mixed Despite New License Agreement
- CSL Limited recently closed a license agreement for a haemophilia B gene therapy candidate which is positive, but there are still risks associated with competition and regulatory approvals.
- The company's near-term outlook is mixed, with the potential upside of increased influenza vaccine demand offset by the prospects of low plasma collection volumes.
- CSL Limited trades at consensus forward FY 2022 (YE June 30) EV/EBITDA and P/E multiples of 28.2 times and 23.7 times, respectively.
For further details see:
CSL Limited: Near-Term Outlook Mixed Despite New License Agreement